Physicians’ Attitudes to Methadone Maintenance Treatment in Nova Scotia Jessica Dooley*, M.Sc. Candidate Dr. Susan Kirkland*, Ph. D. Dr. Mark Asbridge*,

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

Alcohol screening and brief intervention delivery to an Irish cohort of opiate dependent methadone maintained patients. Catherine Darker (PhD) Department.
Bringing Opioid Substitution Treatment to scale Dr. M. Suresh Kumar Inter-country Consultation on Preventing HIV among IDUs Scaling Up: From Evidence to.
Title: PEOPLE LIVING WITH HIV/AIDSIN EGYPT: ROLE OF COMMUNITY PHARMACIST Authors: Nahla Maher Hegab Pharmacy graduate. Institution: College of pharmacy,
Putting the Pieces Together Perspectives from an Opioid Addiction Treatment Program.
National Drug Programme Delivery Unit Supporting the implementation and quality delivery of drug treatment services. Drug Treatment in Prisons Future Directions.
1 HIV and Aging: an Interprofessional Approach Le-Ann Dolan Program Director Canadian Working Group on HIV and Rehabilitation March 19, 2011.
FACTORS HINDERING ATTITUDE TO TREATMENT AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE NIGER DELTA, NIGERIA by AGOFURE OTOVWE and OYEWOLE OYEDIRAN.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2009.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
Community Opioid Addiction Program Tara McIntyre, Addiction/Mental Health Counsellor Megan Neill, Coordinator/Trainer of Specialized Programs.
Aboriginal Access to Health Care Systems Ontario Aboriginal Health Advocacy Initiative.
Developments in Community - Based Drug Treatments Lesley Peters
.  Introduction to Methadone Maintenance Therapy (MMT)  Introduction to Harm Reduction  Benefits of MMT  One Patient’s Perspective  Misconceptions.
Is Health Education Important in Schools?
1 AIDS 2010 Vienna, July 2010 HIV/AIDS and People from Countries where HIV is endemic – Black people of African and Caribbean descent living in Canada.
Peterborough Drug Strategy
Meeting the health needs of older drug users Dr Muriel Simmonte NHS Lothian Primary Care Facilitator Team/East Lothian Locality Drug Clinic.
HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Signe ROTBERGA UNODC, Baltic States 5 November.
Hepatitis C, Drug Use and Stigma Liz Allen. What it is Hepatitis C? Hepatitis C is a blood-borne virus Can cause serious damage to the liver First indentified.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
 To what extent is IMCI implemented in NWP and what are the obstacles to its implementation?  What is the impact of IMCI in NWP?  What is the impact.
Scientific Evidence Module 2. The evidence of effectiveness Most research is on methadone, much less on other medications Has proven effective for the.
OPIOID SUBSTITUTION THERAPY
Inequities in Responding to HIV and Hepatitis C in Atlantic Canada Susan Kirkland PhD, C Marshall MPA, M Dykeman PhD, G Mugford PhD, J MacDonald MN, I.
For Pain or Not for Pain: Methadone Madness
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
Module 7: Physical Health Needs Assessment. Objectives To understand the concept of harm minimisation. To be aware of the physical risks involved in drug.
® Introduction Changes in Opioid Use for Chronic Low Back Pain: One-Year Followup Roy X. Luo, Tamara Armstrong, PsyD, Sandra K. Burge, PhD The University.
Building the Capacity of the Health and Social Care System in Case Management J. Csiszar MD. MSc. MBA IAS Conference July 2010 “ HELP” HIV/AIDS Education.
Epilepsy and WHO | 17 Oct |1 | WHO's six-point agenda The overarching health needs 1.Promoting development 2.Fostering health security The strategic.
Issues in malaria diagnosis and treatment May 31, 2007 Jacek Skarbinski, MD Malaria Branch Centers for Disease Control and Prevention.
1 Presentation to the Academy Health Annual Research Meeting 2006 Brandeis University Schneider Institute for Health Policy June 26, 2006 Research supported.
Practice and Predictors of self-medication among urban and rural adults in Sri Lanka, three decades after Market Economic Reforms Dr. Pushpa Ranjan Wijesinghe.
Physician Practice Style and Barriers to Referral: Los Angeles Women’s Health Study Danielle Rose Ash, PhD VA HSR&D/Greater Los Angeles Care System Co-Authors:
Clinical Management of Substance Misuse Dave Marteau Prison Health
Role of harm reduction in HCV prevention in France: from research to scale up Bruno Spire & Patrizia Carrieri.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
Injection Drug Use and Hepatitis C What Can We Do About It? Wilson M. Compton, M.D., M.P.E. Deputy Director National Institute on Drug Abuse.
Zach Walsh University of British Columbia This study examined the use of cannabis as a substitute for alcohol and other psychoactive.
Opioid Pharmacotherapy: An Introduction Walter Ling, MD Integrated Substance Abuse Programs (ISAP) UCLA International Symposium on Drug Abuse and Addictive.
School of Public Health and Community Medicine How policies and repressive law- enforcement fuel the HIV epidemic among people who inject drugs Professor.
Barriers to Providing Health Services for HIV/AIDS, Hepatitis C Virus Infection, and Sexually Transmitted Infections in Substance Abuse Treatment Programs.
Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.
Optimization of psychotropic drug prescription in nursing home patients with dementia: the PROPER study (PRescription Optimization of Psychotropic drugs.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Module IV - Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS.
BEST PRACTICE PORTAL BEST PRACTICE PORTAL project presentation to the Scientific Committee Ferri et al Lisbon, 16th July 2010.
Single Competency Framework for Prescribers National Prescribing Centre (2012)
Buprenorphine {Suboxone®, Subutex®}
Methadone Maintenance System Performance Measures – 2011/2012 Office of the Provincial Health Officer January 28, Dr. Eric Young, MD, MHSc, CCFP,
…Implications for Wales Josie Smith Programme Lead for Substance Misuse, Public Health Wales TOWARDS A HEALTH BASED APPROACH.
MARYLAND LOCAL OVERDOSE FATALITY REVIEW TEAM PROGRAM CHRISTINE TRUONG MHS CANDIDATE, MENTAL HEALTH.
Services and C Leon Wylie Lead Officer Hepatitis Scotland.
Improving risk factor management for patients with poorly controlled type 2 diabetes: a systematic review of non-pharmaceutical interventions in primary.
Non-Medical Staff Knowledge, Beliefs and Practices about HIV and Hepatitis for Injection Drug Users Rowe, KA 1, Tesoriero, JM 1, Heavner, KK 1, Rothman,
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Dr Sue Pritchard Shipston Medical Centre.  Chronic relapsing condition – similar to others treated in primary care  Mortality 14 x higher for age matched.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
PHARMACEUTICAL GUIDELINES: BASIC PRINCIPLES AND STATUTES.
Thomas F. Babor, Ph.D., MPH Dennis McCarty, Ph.D.
Integrating HIV, TB and Addiction Treatment in Malaysian Prisons
Jonathan Mermin, MD, MPH RADM, USPHS
PrEP introduction for Adolescent Girls and Young Women
Head of Research centre
Enhancing Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness Considerations  Job F.M. van Boven, PharmD, PhD,
AIDS 2018 | Abstract No. TUPDC0102 | Tuesday July 24, 2018
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Share your thoughts on this presentation with #IAS2019
Baseline characteristics of people who inject drugs enrolled in the Montreal Hepatitis C Cohort (2004–2017), by prescribed dosage of opioid agonist treatment,
Presentation transcript:

Physicians’ Attitudes to Methadone Maintenance Treatment in Nova Scotia Jessica Dooley*, M.Sc. Candidate Dr. Susan Kirkland*, Ph. D. Dr. Mark Asbridge*, Ph. D. Dr. John Fraser †, M.D. *Department of Community Health and Epidemiology, Dalhousie University † Direction 180, North End Community Health Centre

Introduction 60,000-90,000 Canadians misuse opioids Methadone Maintenance Treatment (MMT) is an effective treatment  Daily dosing with methadone (a long-acting opioid agonist) to prevent withdrawal symptoms, cravings and euphoric effects of opioids Extent to which policies and programs are developed and accessible varies between geographical/professional settings and facilities Office-based delivery suggested as a way of improving access and capacity Success of such a model depends on willingness of physicians to deliver it

Public health implications of opioid misuse Associated conditions include:  HIV, hepatitis C, overdose, suicide, endocarditis, abscesses, infection, poor nutrition, adverse drug interactions (Fisher et al., 2004, Hser et al., 2001, Health Canada, 2007) Associated co-morbidities include:  Poly-drug dependence, hypertension, diabetes, asthma, chronic liver disease, cirrhosis (Gossop et al., 1997; Haydon, et al., 2003, Brooner et al., 1997; Darke and Ross, 1997) Premature mortality is characteristic (Hser et al., 2001, Millson et al., 2004) Effects extend to families and communities  Blood borne diseases, criminality, economic implications ( Fisher et al., 2004; Hser et al., 2001; Wall et al., 2001 )

Efficacy and effectiveness of methadone Randomized controlled trials have shown methadone to be pharmacologically efficacious and safe (Novich et al., 1993; Kreek, 1973, Donny et al., 2005) Reduces opioid use, use of other illicit drugs, frequency of drug injection, high risk drug use behaviours, criminal activity, morbidity, mortality (Strain et al., 1993; Thiede et al., 2000; Johansson et al.; 2007, Fairbank et al., 1993, Dolan et al., 2003; Gossop et al., 2003, Willner-Reid et al., 2007; Millson et al., 2007; Fabris et al., 2006; Bell et al., 1997, Langendam et al., 2001; Brugal et al., 2005; Caplehorn and Drummer, 1999) Office-based MMT shown to be effective in numerous RCTs (Fiellin et al., 2001, Gossop et al., 1999, 2003) High patient and provider satisfaction (Fiellin et al., 2001) Advantages may include reduced stigma, more attention to medical and mental health concerns, easy geographical access, improved treatment retention (Fiellin et al., 2001; Salsitz et al., 2000).

Current Canadian context (Popova et al., 2006)

Overall objectives Assess acceptability of office-based MMT among non-specialist physicians in Nova Scotia Determine extent to which office-based MMT has the potential to enhance accessibility and capacity Establish the context in which office-based MMT could be integrated in Nova Scotia

Methods survey of population of all non-specialist physicians in Nova Scotia (1170) using OPINIO software  Administered twice, 10 days apart  Clarify attitudes about: Illicit drug use and maintenance-oriented treatment Treatment of opioid-dependent individuals in their practices Barriers and facilitators to MMT delivery in private office- based practice

Acceptability of office-based MMT Key Measures:  Willingness to participate in office-based MMT  Perceived barriers and facilitators to office-based MMT  Attitudes towards drug use Disapproval of drug use scale (DDU)  Attitudes towards principles of harm reduction Abstinence orientation scale (AOS)  Knowledge of the risks and benefits of MMT Test of knowledge of MMT (KNOW) (Caplehorn, 1996)

Preliminary Results (n=124) AgeSexCommunity Size Medical School Training in Addiction Medicine License to prescribe methadone for opioid dependence

Scale Scores ScaleGroupMeanSD KNOWAll (n=123) Licensed (n=11) Unlicensed (n=112) DDUAll (n= 124) Licensed (n=11) Unlicensed (n=113) AOSAll (n=122) Licensed (n=11) Unlicensed (n=111)

Barriers influencing decision to be involved in MMT delivery

Willingness to provide office-based MMT

Potential limitations Response rate Survey error Researcher bias Response selection bias Item bias Social desirability bias Generalizeability

Preliminary Conclusions Considerable acceptance of MMT in the province Potential for improved access to MMT in the province Areas for improvement for integration of MMT clearly highlighted  Education  Interaction with other providers  Support Services

Support In association with: The Atlantic Interdisciplinary Research Network for Social and Behavioural Issues in HIV/AIDS and Hepatitis C (AIRN) The College of Physicians and Surgeons of Nova Scotia Funded by: Canadian Institutes of Health Research Master’s Award Dalhousie University Faculty of Medicine Marvin Burke Award